Saturday 17 October 2026
Export PBM’s income statement to Excel — free account
Psyence Biomedical Ltd.
In the quarter to September 2025, EPS was flat and free cash flow fell 707.2%, each against the same quarter a year earlier.
4.22
0.10
−2.31%
Follow PBM
| Older periods | Mar '24 | Sep '24 | Mar '25 | Sep '25 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.09 | 0.64 | 11.04 | 8.09 |
Net Debt/EBITDA |
0.00 | 1.70 | 0.00 | 4.78 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | — | 0.00 | |
Capex/Depreciation |
(28.50) | (3.56) | — | (0.08) | |
Interest Coverage |
— | (312.73) | — | (537.96) | |
Research and Development Expense of Revenue |
— | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | — | 0.00 | |
Cash per Share |
0.00 | 350.38 | 0.00 | 30.37 | |
Shareholders Equity per Share |
0.00 | (224.12) | 0.00 | 50.07 | |
Interest Debt per Share |
— | 0.00 | — | 0.00 | |
Book value per Share |
0.00 | (224.12) | 0.00 | 50.07 | |
Free Cash Flow |
(2.95) | (1.52) | — | (2.03) | |
Working Capital |
(10.98) | (1.27) | 5.97 | 6.69 | |
Capital Expenditures |
(0.01) | (0.01) | — | 0.00 | |
Net Current Asset Value |
(10.98) | (1.27) | 5.97 | 6.69 | |
| Other line items | |||||
Quick Ratio |
0.07 | 0.59 | 10.61 | 7.82 | |
Revenue per Share |
— | 0.00 | — | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | — | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Average Receivables |
0.44 | 0.09 | 0.10 | 0.11 | |
Average Assets |
129.47 | 129.37 | 133.12 | 14.61 | |
Average Common Equity |
116.84 | 0.13 | 4.09 | 4.19 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates